Although chronic blood transfusion is increasingly indicated in patients with sickle cell disease, measuring resulting iron-overload remains a challenge. Children without viral hepatitis enrolled in two trials for stroke prevention were examined for iron-overload (75%+/-0%; patients/observations: 8/9). Most patients with SF≥3000 ng/ml had a TIL≥100 mg/kg (95.3+/-6.7%; patients/observations: 7/16) or a LIC≥10 mg/gm dry liver weight (87.7%+/-4.3%; patients/observations: 11/18). Although SF changes are non-linear, levels <1500 ng/ml indicated mostly acceptable iron-overload; levels ≥ 3000 ng/ml were specific for significant iron-overload and were associated with liver injury. However, to determine accurately iron-overload in patients with intermediately elevated SF levels, other methods of iron assessment are required. The trials described herein are registered with clinicaltrials.gov under identifiers NCT00000592 and NCT00006182.
Background
Increasing numbers of patients with sickle cell disease (SCD) are receiving chronic blood transfusions for the prevention or management of disease-related complications. As a result, these patients require treatment with either chelator drugs 1 or exchange transfusion 2 to prevent tissue injury from iron-overload. Serum ferritin is a non-invasive measure widely used to monitor iron load. [1] [2] [3] However, the relationship between serum ferritin to other iron load measures varies among studies. [4] [5] [6] [7] [8] [9] [10] [11] [12] Serum ferritin levels increase in inflammatory states, thus levels can be variable over relatively short time frames. 13 In patients with thalassemia cured with bone marrow transplantation, 10 liver iron concentrations (LIC) obtained from liver biopsy correlated more closely with iron stores measured by phlebotomy than serum ferritin. To better characterize measures of ironoverload in children with SCD, this study examined patients enrolled in two clinical trials in which blood transfusion was evaluated for stroke prevention. 14, 15 The relation of serum ferritin to iron load estimated from transfusion history and LICs was examined.
Methods

Study population
STOP was a prospective randomized clinical trial of children with SCD who were identified as having risk of stroke by transcranial Doppler ultrasound (TCD). 14 The children were randomly assigned to either chronic blood transfusions or observation and followed to assess the occurrence of stroke. In the follow-up study by the same investigators, STOP2, patients who were initially at risk for stroke and whose TCD velocities normalized after at least 30 months on chronic transfusion were randomly assigned either to continue or cease transfusion therapy. 15 For personal use only. on July 15, 2017. by guest www.bloodjournal.org From During the course of both trials, enrolled patients were evaluated every three months, with history review, physical examination and laboratory tests. Both quarterly tests and annual viral hepatitis serology were performed at the trial core laboratory at Medical College of Georgia (Augusta, GA) on randomized patients, as described in detail elsewhere. 11 Briefly, serum chemistries, including alanine transaminase (ALT), were measured by DuPont RXL Chemistry Analyzer and serum ferritin by Abbott AXSYM system immunoassay. Only blood chemistry measures assayed at the core laboratory were examined in the current study (collected only after patient randomization). To reduce possible acute phase reactant effect, 13 laboratory measures obtained within 2 weeks before or after a documented infection or SCD-related complication or within 2 weeks after a surgical procedure were excluded. Transfusion intervals in patients who were enrolled in both trials were assumed to be the same between studies as during study periods. Exchange transfusion use was only documented after randomization during the course of the trials.
Permission for the current study, which included collection of additional data pertaining to 
Transfusion iron load
Serum ferritin levels were compared to two benchmark measures of iron load: transfusion iron load (TIL) and liver iron concentration (LIC). TIL was estimated from the cumulative blood volume received in patients that only received simple transfusions, 14 prior to start of chelation therapy. Transfusion volume data from the onset of the stroke prevention program was available only in the first STOP trial. Patients documented with more than 10
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From transfusions prior to randomization or that received exchange transfusion(s) were excluded from this analysis. For the comparison between serum ferritin and TIL, data were censored if transfused blood volume information was missing on >1 consecutive transfusion; otherwise missing transfusion volume was assumed to be equal to average patient transfusion dose. To calculate the amount of iron received, blood unit hematocrit was estimated to be 60%, based on blood preservatives data recorded during the study, and 1 ml of red blood cells was estimated to contain 1 mg of iron. 16 Each set of sampled measures was analyzed separately, after which results were averaged. 22 Factors that may affect serum ferritin or ALT change were examined using mixed models.
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Results
Study population
Of the 277 enrolled patients that had clinical trial study visits and documented viral hepatitis serology, 6 (2%) were excluded (hepatitis C, n=4; hepatitis B, n=1; hepatitis B and C, n=1). Of the remaining 271 patients, 163 were randomized subjects (86 in STOP only, 38 in STOP2 only, 39 in both) and 108 were STOP2 patients observed on transfusion that were not randomized in either study. Fifty-four percent of patients (n=89) For personal use only. on July 15, 2017. by guest www.bloodjournal.org From were female, 1% (n=2) were diagnosed with hemoglobin (Hb) S beta-0 thalassemia, the remainder with Hb SS. Twenty-four of percent of patients (n=39) participated in both STOP and STOP2. Average age at start of transfusion therapy was (+/-standard deviation) 8.5+/-3.4 years. For the most part (97% of the time, median 28 days), transfusions were administered within < 60 days of each other. The average volume of simple transfusion was 11.0+/-3.6 cc/kg. Chelation therapy was documented in 60% (n=98) of patients, starting on average after 33+/-20 transfusions; 1% (n=2) initially received deferasirox, the remainder desferrioxamine. Chelation therapy was administered on average 60+/-27% of the time while patients where on transfusion, according to quarterly visit records. Eleven percent (n=18) of patients had a splenectomy, 50% (n=9) of these occurred after start of transfusion therapy. Exchange transfusion use was reported in 42% (n=68), 54% (n=37) received 9, 12, 17 Twenty-three percent (n=19) of patients had a second analyzable LIC, 11% (n=9) a third, and 1% (n=1) a fourth one. 
Iron measure comparisons
Median serum ferritin change with increasing number of transfusions, TIL and LIC are presented in Figure 1 and Averaged correlation between serum ferritin and TIL was r=0.70 +/-0.09; when TILs <50 mg/kg were excluded, r=0.47+/-0.14. Averaged correlation between serum ferritin and LICs was r=0.55 +/-0.06. Serum ferritin ROC AUC are presented in Figure 2 . Predictive value of serum ferritin ranges compared to iron load ranges are presented in Table 2 . All serum ferritin measures ≥ 4000 ng/ml were associated with LIC ≥ 10 mg/gm dw (8 patients,
observations).
Relation between TIL and LIC obtained within a month of start of chelation therapy was estimated in 15 patients on simple transfusion (STOP2 transfusion volume data in 8 patients that were never randomized, and in 5 patients prior to randomization, was estimated to be the same as the average volume administered in the study). Correlation coefficient was r=0.64. Linear regression relation 10 was expressed as: TIL (mg/kg) = 9.0 x LIC (mg/gm dw), assuming that the amount of blood received prior to the trials was negligible.
To examine if trends in serum ferritin levels can be used as a qualitative measure of increasing or decreasing iron-overload, serum ferritin linear regression trends over time were compared to LIC pair trends (all serum ferritin measures within 4 months before first or after last LIC were included). Fifteen LIC pairs in 10 patients were examined. These were obtained on average 1.6+/-1.3 years apart (range 0.5 to 4.7). Serum ferritin and LIC trends were significantly more likely to be in the same direction (87%, increasing n=8, decreasing n=5; p=0.007), than in the opposite direction (13%, increasing serum ferritin and decreasing LIC, n=2).
Liver injury and serum ferritin
Of patients on transfusions on whom ALT levels were available, 57% (85/150) had at least one ALT measure Table 3 .
The presence or absence of liver fibrosis was described in 90% of biopsies (n=75;
trichrome stain documented in 69). In these, fibrosis was absent in 56% (n=42), mild in 37% (n=28) and moderate to severe in 7% (n=5). When liver biopsies with highest degree
fibrosis average serum ferritin was 3571+/-2158 ng/ml (n=4, p=0.234). Respective values for LIC were 14.0+/-8.2 mg/gm dw (n=45) and 25.5+/-15.6 mg/gm dw (n=4, p=0.097). In univariate mixed models, degree of fibrosis was associated with ALT (p=0.018) and approached significance with gamma glutamyl transferase levels (p=0.051) and with number of transfusions (p=0.081).
Discussion
The natural history of iron-overload was examined in chronically transfused children with SCD and without viral hepatitis, who were observed for up to 10 years in two consecutive stroke prevention trials. These trials were conducted at a time when most patients received chelation as injectable desferrioxamine, which can be difficult to administer.
1 This allowed an analysis over a wide range of iron-overload. Serum ferritin level changes appeared non-linear when compared to increasing iron load iron measured by TIL or LIC.
After an initial rapid rise, serum ferritin rate of change seemed to slow after reaching approximately 1500-2500 ng/ml, despite evidence of increasing iron load. After further iron-overload, patients developed high levels of serum ferritin (≥3000 ng/ml). Serum ferritin measures above this level appeared to be associated with both increased LIC and liver injury, as estimated by ALT levels.
Intra-cellular ferritin is a hollow protein shell made of 24 heavy (H) or light (L) subunits that stores iron. 24 Synthesis is differentially regulated at a post-transcriptional level, mediated by iron binding proteins. 25 L-subunits contain iron storage facilitating ferroxidase enzymatic activity, 24 and are approximately 3 to 4 times more abundant than H-subunits in the liver of normal individuals. 26 Cardiac ferritin is composed principally of H-subunits.
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During iron-overload, liver ferritin content increases more than fourfold and is further enriched in L-subunits. 26 However, liver hemosiderin, which is formed from degraded ferritin in the lysome, is constituted predominantly of H -subunits. 26 L-subunits are actively secreted in response to iron and inflammatory cytokines, 28 by an unknown mechanism. In patients with thalassemia major on chronic tranfusion, 5 glycosylated serum ferritin levels reached a plateau after 100 units, consistent with a rate limited active secretion process.
Rapid serum ferritin level changes at low iron load, and slower rate of change at moderate iron load levels was also described in patients with hemochromatosis undergoing phlebotomy, 4 and was noted in a previous analysis of STOP data. 11 Following a flattened response, a near exponential increase in serum ferritin was observed at high LIC levels in patients with a variety of hematological conditions or hemacromatosis. 4 In patients with thalassemia major, un-glycosylated (and thus presumably not actively secreted) serum ferritin continued to rise with further transfusions. 5 Authors proposed that serum ferritin changes beyond the flattened phase was due to leakage from damaged hepatocytes. An association between ALT and serum ferritin levels was observed in an iron-overload rat model 29 and in patients on chronic transfusion for thalassemia major 5, 30 or acquired anemias. 31 It can also occur in patients with acute liver injury without iron-overload. 4 In the current study, most patients developed elevated ALT levels during the course of transfusion therapy. However, peak ALT elevations and degree of liver fibrosis were mostly mild, consistent with previous observations. 9 ALT level changes were significantly associated with iron load estimated both by TIL and LIC. A modest but significant association between fibrosis and LIC noted in a previous report 9 was not evident in the present study, probably because only a small number of patients with moderate to severe
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From fibrosis were observed, or because of other factors. The association between ALT and serum ferritin was evident in patients with iron load assessed by LIC, and in general in patients that received more than 50 transfusions, suggesting that in children with SCD, this phenomenon occurs after prolonged exposure to chronic transfusion.
Weight at start of transfusion therapy was also associated with increased serum ferritin levels in the multivariate analysis. Serum ferritin changes were not significantly associated with other variables, such as gender 4 or splenectomy. Possible other reasons for low serum ferritin levels, such as low ascorbic acid levels 32 or asymptomatic mutations of the ferritin L-subunit gene 33 , were not examined.
Utility of serum ferritin as a measure of iron load has been questioned. 3, 12 Poor predictability of serum ferritin can be in part attributed to when data is sampled in relation to degree of iron load. Indeed, serum ferritin levels correlate poorly with iron load when data points are obtained in the flattened part of the response curve. This effect can be simulated with TIL, by removing data points with TIL <50 mg/kg, as illustrated in Figure 2 .
An analysis comparing serum ferritin ranges to iron level ranges best summarizes when serum ferritin may be useful as a clinical tool to monitor iron, and when it is of limited value (see Table 2 ).
This study also examined LIC performed in a clinical setting as a measure of ironoverload. Complications from liver biopsy requiring hospitalization were observed in 2%.
One patient developed a liver abscess, similar to a previous report. 34 No patients died from the procedure. 35 In a smaller group of patients, the linear regression equation between TIL and LIC assayed by ICPMS, which was the predominant method used, was
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From similar to that observed in patients with thalassemia major following bone marrow transplantation. 10 In that study, TIL in mg/kg measured by phlebotomy was equal to 10.6 times LIC in mg/gm dw, assayed by atomic absorption spectroscopy. In the present study, In light of these observations, an approach to monitor iron-overload can be proposed, transfusions at 10 cc/kg). Serum ferritin levels <1500 ng/ml (e.g., before the response curve flattens), indicate acceptable iron load in most patients. However, approximately 15% to 25% of patients may be "high" 11 or "low" serum ferritin responders. These can be detected by comparing serum ferritin to TIL prior to start of chelation. "Low responders," once detected, may require a lower serum ferritin threshold, as seemingly adequate
) overcomes much of the variability seen over time in individual patients, and can also help avoid over chelation, another potential source of toxicity. Serial ALT measures can also be informative, as levels change in response to iron-overload. 31, 37 In contrast, >3/4 of patients with serum ferritin levels However, there is no way of knowing with precision if a person with serum ferritin levels in the ≥ 1500-<3000 ng/ml range who was on transfusion and chelation therapy for a period of time, has an acceptable iron load or has developed significant iron-overload. For these reasons, optimal iron load assessment should also include periodic (yearly) tissue iron For personal use only. on July 15, 2017. by guest www.bloodjournal.org From determination, especially in patients with intermediately elevated serum ferritin levels (≥1500-<3000 ng/ml).
Non-invasive methods of tissue iron assessment include the investigational superconducting interference device susceptometer (SQUID) 7, 41 and MRI. [42] [43] [44] [45] Clinically meaningful correlations between MRI R2, 42, 43 R2* 43, 45 and biopsy derived LICs were reported in patients with transfusion iron-overload and are currently the most accessible non-invasive methods. Cardiac MRI should be considered in patients with a prolonged history of transfusions, as heart iron-overload seems to follow that of the liver. 44 Elucidating how tissue iron levels are measured by MRI 46 may help improve the method further and allow its precise calibration and standardization, without need of tissue biopsies.
In patients with thalassemia major, 3 serum ferritin levels exceeding 2500 ng/ml were associated with decreased survival from iron-overload-related heart complications.
Although in patients with SCD, the relationship between iron measures and outcome needs to be further defined, in a recent study, transfused patients with serum ferritin ≥ 2000 ng/ml or LIC≥10 mg/gm dw had similar risk of death as those with thalassemia major with equivalent iron load and transfusion history. 47 In the current study, most patients became iron-overloaded during the course of the trials, as most developed serum ferritin levels >2500 ng/ml after approximately 30 transfusions, reflecting difficulties in administering desferrioxamine. Studies of populations at risk, including surveys utilizing TIL and tissue iron assessments, will help ascertain novel iron removal methods 1 1000+/-250 4/4 -75.0 25.0 *averages from 1000 random data samplings (one observation within serum ferritin range per patient selected at each sampling; same patient may be represented in >1 serum ferritin range). All LICs in this analysis were > 2.5 mg/gm dw. SD: sampling standard deviation, dw: dry liver weight. For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
